Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace innovation—bringing ideas, products and services to life to advance the health and well-being of people around the world. We believe in collaboration, and that has led to breakthrough after breakthrough, from medical miracles that have changed lives, to the simple consumer products that make every day a little better.

Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Our Family of Companies comprises:

- The world’s sixth-largest consumer health company
- The world’s largest and most diverse medical devices company
- The world’s sixth-largest biologics company
- And the world’s fifth-largest pharmaceuticals company

We have more than 265 operating companies in more than 60 countries.

Johnson & Johnson was founded in 1886 and is headquartered in New Brunswick, US

CEO

CFO

Independent Director

VP, Global Corporate Affairs

Executive VP, CHRO

Executive VP & CSO

Johnson & Johnson has an office in New Brunswick

New Brunswick, US (HQ)

One Johnson & Johnson Plaza

Johnson & Johnson's revenue was reported to be $71.9 b in FY, 2016 which is a **3% increase** from the previous period.

USD

## Revenue (FY, 2016) | 71.9 b |

## Revenue growth (FY, 2015 - FY, 2016), % | 3% |

## Gross profit (FY, 2016) | 50.2 b |

## Gross profit margin (FY, 2016), % | 70% |

## Net income (FY, 2016) | 16.5 b |

## EBIT (FY, 2016) | 16.5 b |

## Market capitalization (25-Jul-2017) | 363.3 b |

## Cash (31-Dec-2016) | 19 b |

## EV | 366.7 b |

Johnson & Johnson's current market capitalization is $363.3 b.

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 71.3 b | 74.3 b | 70.1 b | 71.9 b |

## Revenue growth, % | 4% | (6%) | 3% | |

## Cost of goods sold | 22.3 b | 22.7 b | 21.5 b | 21.7 b |

## Gross profit | 49 b | 51.6 b | 48.5 b | 50.2 b |

## Gross profit Margin, % | 69% | 69% | 69% | 70% |

## Sales and marketing expense | 21.8 b | 22 b | 21.2 b | 19.9 b |

## R&D expense | 8.2 b | 8.5 b | 9 b | 9.1 b |

## Operating expense total | 30 b | 30.4 b | 30.2 b | 29 b |

## Depreciation and amortization | 4.1 b | 3.9 b | 3.7 b | 3.8 b |

## EBIT | 16.4 b | 21.6 b | 19.2 b | 16.5 b |

## EBIT margin, % | 23% | 29% | 27% | 23% |

## Interest expense | 580 m | 533 m | 552 m | 726 m |

## Interest income | 74 m | 67 m | 128 m | 368 m |

## Pre tax profit | 15.5 b | 20.6 b | 19.2 b | 19.8 b |

## Income tax expense | 1.6 b | 4.2 b | 3.8 b | 3.3 b |

## Net Income | 13.8 b | 16.3 b | 15.4 b | 16.5 b |

- Source: SEC Filings

USD | Y, 2010^{} | Y, 2011^{} | Y, 2012^{} | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|---|---|---|

## Cash | 15.8 b | 19.4 b | 24.5 b | 20.9 b | 14.5 b | 13.7 b | 19 b |

## Inventories | 7.9 b | 8.2 b | 8.1 b | 8.1 b | |||

## Current Assets | 56.4 b | 59.3 b | 60.2 b | 65 b | |||

## PP&E | 16.7 b | 16.1 b | 15.9 b | 15.9 b | |||

## Goodwill | 22.8 b | 21.8 b | 21.6 b | 22.8 b | |||

## Total Assets | 132.7 b | 131.1 b | 133.4 b | 141.2 b | |||

## Accounts Payable | 6.3 b | 7.6 b | 6.7 b | 6.9 b | |||

## Total Debt | 13.3 b | 15.1 b | 12.9 b | 22.4 b | |||

## Current Liabilities | 25.7 b | 25.1 b | 27.7 b | 26.3 b | |||

## Retained Earnings | 89.5 b | 97.2 b | 103.9 b | 110.6 b | |||

## Total Equity | 71.2 b | 70.4 b | |||||

## Debt to Equity Ratio | 0.2 x | 0.3 x | |||||

## Debt to Assets Ratio | 0.1 x | 0.1 x | 0.1 x | 0.2 x | |||

## Financial Leverage | 1.9 x | 2 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | 13.8 b | 16.3 b | 15.4 b | 16.5 b |

## Accounts Receivable | (632 m) | (247 m) | (433 m) | (1.1 b) |

## Inventories | (622 m) | (1.1 b) | (449 m) | (249 m) |

## Accounts Payable | 1.8 b | 955 m | 656 m | |

## Cash From Operating Activities | 17.4 b | 18.5 b | 19.3 b | 18.8 b |

## Purchases of PP&E | (3.6 b) | (3.7 b) | (3.5 b) | (3.2 b) |

## Cash From Investing Activities | (5.1 b) | (12.3 b) | (7.7 b) | (4.8 b) |

## Cash From Financing Activities | (6.1 b) | (12.3 b) | (10.8 b) | (8.6 b) |

## Interest Paid | 596 m | 603 m | 515 m | 730 m |

## Income Taxes Paid | 3.2 b | 3.5 b | 2.9 b | 2.8 b |

USD | Y, 2016 |
---|---|

## EV/EBIT | 22.2 x |

## EV/CFO | 19.5 x |

## Revenue/Employee | 566.7 k |

## Debt/Equity | 0.3 x |

## Debt/Assets | 0.2 x |

## Financial Leverage | 2 x |

Johnson & Johnson's Facilities was reported to be 119 in FY, 2016, which is a 2% decrease from the previous period

Acquired Company | Date | Deal Size |
---|---|---|

Actelion Pharmaceuticals | January 26, 2017 | $30 b |

Abott Medical Optics | September 16, 2016 | $4.3 b |

Vogue International | June 02, 2016 | $3.3 b |

Novira Therapeutics | November 08, 2015 | |

XO1 | March 20, 2015 | |

Alios BioPharma | September 30, 2014 | $1.8 b |

Aragon Pharmaceuticals | June 17, 2013 | $1 b |

Source: 32 public H-1B filings from Johnson & Johnson